Sales, business progress and supply risks arising from COVID-19 and other infectious diseases
First written in FY2020. 9 of 13 entries say "Restated". Latest entry: FY2025-H1.
The whole theme swung hardest in 2025: 5 of 15 companies on the "Worse" side.
12 other companies' latest entry also says "Restated".
- FY2025-H1RestatedAnnual report
「During the interim consolidated accounting period, there were no new major risks or significant changes to the business risks described in the annual securities report that management recognized as potentially having a material effect on the financial position, operating results, or cash flows of the consolidated companies, among the matters concerning business conditions and financial matters described in this Semiannual Report.」
It is stated that there have been no material changes regarding sales, business progress and supply risks arising from COVID-19 and other infectious diseases. - FY2024-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
It is stated that there have been no material changes regarding sales, business progress and supply risks arising from COVID-19 and other infectious diseases. - FY2024-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
It is stated that there have been no material changes regarding sales, business progress and supply risks arising from COVID-19 and other infectious diseases. - FY2024-Q1RestatedAnnual report
「During the three-month period ended 30 June, there were no new risks that management recognizes as having the potential to materially affect the financial position, operating results or cash flows of the consolidated companies, and no material changes to the business risks described in the annual securities report for the previous fiscal year.」
It is stated that there have been no material changes regarding sales, business progress and supply risks arising from COVID-19 and other infectious diseases. - FY2023-Q3RestatedAnnual report
「During the cumulative third quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
It is stated that there have been no material changes regarding sales, business progress and supply risks arising from COVID-19 and other infectious diseases. - FY2023-Q2RestatedAnnual report
「During the cumulative second quarter under review, there were no significant changes in the matters described in this quarterly report regarding the business and accounting conditions that management recognizes could materially affect the financial position, operating results and cash flows of the consolidated companies, or in the “Business and Other Risks” described in the securities report for the previous fiscal year.」
It is stated that there have been no material changes regarding sales, business progress and supply risks arising from COVID-19 and other infectious diseases. - FY2022-Q3WorsenedAnnual report
「In the chemicals and overseas businesses, the economic impact of COVID-19 is showing signs of recovery as vaccination rates improve, but the situation has not yet been resolved due to the resurgence of new variants and other factors, and the Company must continue to monitor market trends in Japan and overseas.」
While acknowledging a recovery trend resulting from higher vaccination rates, the disclosure states that risks of lost sales opportunities and stalled business progress remain due to the resurgence of new variants and other factors. - FY2022-Q2MitigatedAnnual report
「In the chemicals and overseas businesses, the economic impact of COVID-19 is showing signs of recovery as vaccination rates improve, but the situation has not yet been fully resolved, and the Company must continue to monitor market trends in Japan and overseas.」
Although the impact of infectious diseases on the Chemicals and Overseas businesses was described as being on a recovery trend, it was not stated that lost sales opportunities and stalled business progress had been completely resolved, and these matters continue to be monitored. - FY2022-Q1RestatedAnnual report
「Against this backdrop, while implementing safety measures such as remote work and staggered working hours in line with government measures to address infectious diseases including COVID-19, our group has pursued various initiatives under the medium-term management plan covering fiscal 2021 to fiscal 2023, which began in fiscal 2021, to establish the business and earnings foundations needed to grow into a "Japanese agricultural solutions company of which Japan can be proud."」
Business operations have continued while implementing remote work and staggered working hours in response to COVID-19 and other infectious diseases. - FY2021-Q3RestatedAnnual report
「In the chemicals and overseas businesses, we were concerned about the loss of sales opportunities and delays in business progress caused by the COVID-19 pandemic. Nevertheless, we worked to develop products using our proprietary technologies, focused on creating functionality in materials that meets customer needs, and conducted sales activities for domestic and overseas business partners, including through remote work.」
Concerns about lost sales opportunities and stalled business progress due to the COVID-19 pandemic continue to be described, as in the previous quarter. - FY2021-Q2RestatedAnnual report
「In the chemicals and overseas businesses, there are concerns that the COVID-19 pandemic may result in lost sales opportunities and delays in business progress.」
The risks of lost sales opportunities and stalled business progress due to the COVID-19 pandemic continue to be described, as in the previous quarter. - FY2021-Q1MaterialisedAnnual report
「On the profit side, expenses declined due to restrictions on sales activities associated with COVID-19, and segment profit was ¥107 million, up 23.1% year on year.」
Restrictions on sales activities associated with COVID-19 actually occurred and were described in terms of lower expenses in the Chemicals business and changes in segment profit. - FY2020First statedAnnual report
「As measures against COVID-19 and other infectious diseases, our group has in principle prohibited meetings, training sessions and other events held in person, and has implemented safety measures such as working from home and staggered working hours. However, if the spread of COVID-19 and other infectious diseases continues for an extended period, delays in deliveries by our group or major business partners and impacts on the procurement of raw materials may affect our group’s operating performance and financial position.」
For COVID-19 and other infectious diseases, restrictions on meetings and training, working from home and staggered working hours have been implemented as countermeasures, and the risks of delivery delays, raw-material procurement issues and impacts on operating performance if the situation becomes prolonged have been newly disclosed.